Psychedelic treatments are rapidly entering the mainstream of medical care delivery in the
United States. Clinical guidelines are urgently needed to ensure well tolerated practice and …

Introduction and aim It is important to understand how mental health practitioners view
recent findings on psychedelic-assisted psychotherapy (PAP) as there is potential this …

In clinical research settings around the world, renewed investigations are taking place on
the use of psychedelic substances for treating illnesses such as addiction, depression …

Mental health problems including depression, anxiety, suicide, and burnout are common
among health care providers. Resilience and well-being are factors thought to protect …

Naturalistic psychedelic use among Canadians is common. However, interactions about
psychedelic use between patients and clinicians in Canada remain unclear. Via an …

The reemergence of psychedelic medicines as clinical treatments has generated
considerable interest in both professional and popular arenas. Although evidence is …

Clinical research on psychedelic-assisted psychotherapy is rapidly advancing in the USA,
with two drugs, psilocybin and MDMA, progressing through a structure of FDA-approved …

There is a resurgence, some say renaissance, of clinical research on psychedelic
substances after decades of dormancy. Recent studies have produced findings suggesting …

Abstract Background and Objectives In recent years, there has been accelerating scientific
and public interest in the use of psychedelics to treat mental health disorders. Our study's …

Abstract The ''psychedelic renaissance''is generating new evidence for psychedelics'
potential to treat numerous mental and substance use disorders. In particular, the United …